After two rough years, health-care venture capitalists are adapting to deal with what could be more tough times ahead.
While medical companies have produced some of the best exits recently-–most notably, Ardian Inc.’s $800 million sale to Medtronic Inc.–-the downturn has left many companies gasping.
“The biggest issue in health-care venture capital is that most of the funds are out of money,” said David Collier, managing director of venture firm CMEA Capital. As a result, “We’ll continue to see bankruptcies in both devices and drug-development companies.”